Free Trial

Brookfield Corporation (NYSE:BN) is Lincluden Management Ltd.'s 7th Largest Position

Brookfield logo with Finance background

Lincluden Management Ltd. lowered its stake in shares of Brookfield Corporation (NYSE:BN - Free Report) by 22.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 626,558 shares of the company's stock after selling 184,923 shares during the quarter. Brookfield comprises 4.2% of Lincluden Management Ltd.'s portfolio, making the stock its 7th largest position. Lincluden Management Ltd.'s holdings in Brookfield were worth $32,791,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of BN. SFE Investment Counsel purchased a new stake in Brookfield in the first quarter worth about $295,000. Guardian Wealth Management Inc. lifted its stake in shares of Brookfield by 4.0% in the first quarter. Guardian Wealth Management Inc. now owns 58,573 shares of the company's stock worth $3,070,000 after buying an additional 2,229 shares in the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Brookfield by 1.4% in the first quarter. Venturi Wealth Management LLC now owns 22,863 shares of the company's stock worth $1,198,000 after buying an additional 306 shares in the last quarter. Templeton & Phillips Capital Management LLC lifted its stake in shares of Brookfield by 2,706.9% in the first quarter. Templeton & Phillips Capital Management LLC now owns 134,088 shares of the company's stock worth $7,028,000 after buying an additional 129,311 shares in the last quarter. Finally, Maestria Partners LLC lifted its stake in shares of Brookfield by 9.6% in the first quarter. Maestria Partners LLC now owns 569,019 shares of the company's stock worth $29,822,000 after buying an additional 50,000 shares in the last quarter. Hedge funds and other institutional investors own 61.60% of the company's stock.

Brookfield Price Performance

Shares of BN traded up $0.14 during midday trading on Friday, hitting $67.59. 1,569,512 shares of the company traded hands, compared to its average volume of 2,290,698. The firm has a 50 day moving average of $61.11 and a 200-day moving average of $57.17. Brookfield Corporation has a 52 week low of $42.21 and a 52 week high of $68.75. The stock has a market cap of $111.43 billion, a price-to-earnings ratio of 241.38 and a beta of 1.66. The company has a debt-to-equity ratio of 1.49, a quick ratio of 1.18 and a current ratio of 1.30.

Brookfield (NYSE:BN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.90 by $0.08. Brookfield had a net margin of 0.76% and a return on equity of 4.20%. The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.36 billion. On average, analysts forecast that Brookfield Corporation will post 3.85 EPS for the current fiscal year.

Brookfield Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Friday, June 13th were paid a $0.09 dividend. The ex-dividend date was Friday, June 13th. This represents a $0.36 dividend on an annualized basis and a dividend yield of 0.53%. Brookfield's payout ratio is currently 128.57%.

Wall Street Analysts Forecast Growth

BN has been the topic of a number of research analyst reports. Royal Bank Of Canada initiated coverage on shares of Brookfield in a research report on Wednesday, June 18th. They set an "outperform" rating and a $81.00 price objective on the stock. Scotiabank decreased their price target on shares of Brookfield from $71.00 to $68.00 and set a "sector outperform" rating on the stock in a research report on Monday, April 7th. Wall Street Zen downgraded shares of Brookfield from a "hold" rating to a "sell" rating in a research report on Saturday, July 12th. JPMorgan Chase & Co. decreased their price target on shares of Brookfield from $66.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Finally, CIBC reduced their price objective on shares of Brookfield from $74.00 to $72.00 and set an "outperformer" rating for the company in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $66.13.

Get Our Latest Research Report on BN

Brookfield Profile

(Free Report)

Brookfield Corporation is an alternative asset manager and REIT/Real Estate Investment Manager firm focuses on real estate, renewable power, infrastructure and venture capital and private equity assets. It manages a range of public and private investment products and services for institutional and retail clients.

Featured Articles

Institutional Ownership by Quarter for Brookfield (NYSE:BN)

Should You Invest $1,000 in Brookfield Right Now?

Before you consider Brookfield, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brookfield wasn't on the list.

While Brookfield currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines